Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Accumulated Depreciation (2022 - 2025)

Stoke Therapeutics (STOK) has 3 years of Accumulated Depreciation data on record, last reported at $8.8 million in Q4 2024.

  • For Q4 2024, Accumulated Depreciation rose 32.63% year-over-year to $8.8 million; the TTM value through Dec 2024 reached $8.8 million, up 32.63%, while the annual FY2024 figure was $8.8 million, 32.63% up from the prior year.
  • Accumulated Depreciation reached $8.8 million in Q4 2024 per STOK's latest filing, up from $6.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $8.8 million in Q4 2024 and bottomed at $4.2 million in Q4 2022.
  • Average Accumulated Depreciation over 3 years is $6.6 million, with a median of $6.7 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation: soared 58.57% in 2023, then skyrocketed 32.63% in 2024.
  • A 3-year view of Accumulated Depreciation shows it stood at $4.2 million in 2022, then skyrocketed by 58.57% to $6.7 million in 2023, then surged by 32.63% to $8.8 million in 2024.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation were $8.8 million in Q4 2024, $6.7 million in Q4 2023, and $4.2 million in Q4 2022.